Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404364 | 0.90 | HTR2C (0.51) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3402983 | 0.89 | HTR2C (0.68) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3403644 | 0.85 | HTR2C (0.49) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3406004 | 0.85 | HTR2C (0.49) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3402572 | 0.84 | HTR2C (0.48) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3402218 | 0.84 | HTR2C (0.41) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13310314 | 0.82 | HTR2C (0.41) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3404329 | 0.82 | CRHR1 (0.44) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3400468 | 0.82 | HTR2C (0.40) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13071984 | 0.82 | HTR2C (0.40) | HTR2CALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | HTR2C 416/4885ALDH1A1 916/4885NPC1 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.